Vaxxinity, hoping to turn bodies into their own drug factories, makes a subdued Wall Street debut

Immunotherapeutic vaccine developer Vaxxinity, with an eye on COVID and some serious CNS diseases, has pulled off a fairly small IPO. The Dallas-based company (with bases around the world), created back in the spring when COVAXX and United Neuroscience came together under the new biotech, had been gunning for a $101 million offering, looking to sell nearly 7 million shares at a price range between $14 and $16.